Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
Overview of the Recent Transaction On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 192,770 shares in Replimune Group Inc (NASDAQ:REPL), a clinical-stage...